Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

OpCT-001

PreclinicalBiologic

BBlueRock Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Photoreceptor DiseaseRecruiting

Primary Photoreceptor DiseasePreclinical

Recruiting

Timeline

Expected Milestones

Q4 2030

PreclinicalRecruiting

Primary Photoreceptor Disease

NCT06789445

Clinical

Trials by Indication[1]

Primary Photoreceptor Disease1 trial

A Phase 1/2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease

Recruiting·BBlueRock Therapeutics·Preclinical·NCT06789445·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OpCT-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OpCT-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OpCT-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BlueRock Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: BBlueRock Therapeutics

Related News